A Phase 1, Randomised, Open Label, 2-period Crossover, Single Centre, 3-arm, Single Dose Study to Investigate the Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsule Formation in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2017
At a glance
- Drugs HTL 18318 (Primary)
- Indications Cognition disorders
- Focus Pharmacokinetics
- Sponsors Heptares Therapeutics
- 08 Feb 2017 Last checked against ClinicalTrials.gov record.
- 02 Feb 2017 Status changed from active, no longer recruiting to completed.
- 04 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jan 2017.